Please ensure Javascript is enabled for purposes of website accessibility

Dow Falls Another 350 Points on Coronavirus Concerns, Worst Week Since 2008

By Mark Prvulovic - Feb 28, 2020 at 4:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Markets around the world are continuing to plunge in what's been the worst week in over a decade.

Markets around the world are seeing continued declines as investors remain worried about the economic implications of the COVID-19 coronavirus outbreak. The Dow Jones Industrial Average is down 350 points (around 1.4%) at the moment, with the index having initially fallen as much as 950 points earlier in the day. Both the S&P 500 and the Nasdaq have fared better, with the S&P down just 0.8% while the Nasdaq ended the day having not moved much at all.

Mexico and Nigeria also announced their first confirmed COVID-19 cases on Friday. Although the World Health Organization (WHO) still has not formally declared the virus a pandemic, the agency has stated that global risk levels were increasing drastically.

A frustrated person watching as the market falls.

Image source: Getty Images.

The White House has continued to reassure the American public, saying that this week's decline in the markets is an overreaction. "Our threat assessment is low and the economy is fundamentally sound. I don't think this stock market plunge is going to have any long-term effect," said National Economic Council Director Larry Kudlow in a Friday morning press briefing.

Treatments are currently in progress

While biotech companies are scrambling to develop and test potential treatments to COVID-19, it will still be quite a while before a vaccine or drug receives full approval. Gilead Sciences (GILD 0.18%) is perhaps the closest to developing a treatment, with the company utilizing its former Ebola drug remdesivir to help reduce COVID-19 patient symptoms. Gilead announced on Wednesday that there will be two phase 3 clinical trials in China testing the drug's effect in human patients.

 

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.33 (0.18%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.